HIK.L Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 18:39):

Stats
Šios dienos apimtis	369 890
Vidutinė apimtis	629 221
Rinkos kapitalizacija	4.24B
EPS	£0 ( 2024-02-22 )
Last Dividend	£25.00 ( 2023-08-10 )
Next Dividend	£0 ( N/A )
P/E	28.13
ATR14	£0.842 (0.04%)

Tūris Koreliacija

Ilgas: 0.07 (neutral)

Trumpas: -0.27 (neutral)

Signal:(57.946) Neutral

Hikma Pharmaceuticals PLC Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Hikma Pharmaceuticals PLC Koreliacija - Valiuta/Žaliavos

-0.08
( neutral )

0.14
( neutral )

-0.03
( neutral )

-0.40
( neutral )

0.08
( neutral )

0.23
( neutral )

Hikma Pharmaceuticals PLC Finansinės ataskaitos

Annual	2023
Pajamos:	£2.88B
Bruto pelnas:	£1.39B (48.35 %)
EPS:	£0.860

FY	2023
Pajamos:	£2.88B
Bruto pelnas:	£1.39B (48.35 %)
EPS:	£0.860

FY	2023
Pajamos:	£0
Bruto pelnas:	£0 (0.00 %)
EPS:	£0

FY	2022
Pajamos:	£2.52B
Bruto pelnas:	£1.27B (50.26 %)
EPS:	£0.840

Financial Reports:

No articles found.

Hikma Pharmaceuticals PLC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
£16.00 (N/A)	£0 (N/A)	£29.52 (N/A)	£0 (N/A)	£25.00 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)

Hikma Pharmaceuticals PLC Dividend Information - Dividend Knight

Dividend Sustainability Score: 9.93 - good (99.32%) | Divividend Growth Potential Score: 3.84 - Decrease likely (23.24%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	£0.500	2006-04-26
Last Dividend	£25.00	2023-08-10
Next Dividend	£0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	36	--
Total Paid Out	£347.38	--
Avg. Dividend % Per Year	1.60%	--
Score	4.06	--
Div. Sustainability Score	9.93
Div.Growth Potential Score	3.84
Div. Directional Score	6.89	--

Next Divdend (Est)
(2024-06-25)

£25.96 Estimate 7.54 %

Dividend Stability

0.30 Poor

Dividend Score

4.06

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
2006	£0	0.00%
2007	£0	0.00%
2008	£0	0.00%
2009	£0	0.00%
2010	£0	0.00%
2011	£0	0.00%
2012	£0	0.00%
2013	£0	0.00%
2014	£0	0.00%
2015	£0	0.00%
2016	£0	0.00%
2017	£0	0.00%
2018	£25.40	1.92%
2019	£34.00	1.99%
2020	£36.22	1.82%
2021	£37.70	1.47%
2022	£42.00	1.92%
2023	£54.52	3.36%
2024	£0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for LSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SOLI.L	Dividend Knight	2023-09-07	Semi-Annually	29	1.07%
IVPU.L	Dividend Knight	2023-07-20	Quarterly	18	2.34%
BSC.L	Dividend Knight	2023-10-05	Semi-Annually	20	5.24%
PHAR.L	Dividend Junior	2023-06-15	Sporadic	12	1.15%
FORT.L	Dividend Knight	2023-09-21	Annually	9	3.03%
ABD.L	Dividend Junior	2023-08-10	Semi-Annually	35	0.96%
TEP.L	Dividend Knight	2023-07-20	Semi-Annually	25	2.14%
LGEN.L	Dividend Knight	2023-08-24	Semi-Annually	32	4.61%
CHRT.L	Dividend Knight	2023-08-24	Semi-Annually	19	1.43%
REL.L	Dividend Knight	2023-08-03	Semi-Annually	32	1.59%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0661	1.500	8.68	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0406	1.200	8.65	10.00	[0 - 0.3]
returnOnEquityTTM	0.0866	1.500	-0.149	-0.223	[0.1 - 1]
payoutRatioTTM	0.721	-1.000	2.79	-2.79	[0 - 1]
currentRatioTTM	1.568	0.800	7.16	5.73	[1 - 3]
quickRatioTTM	0.831	0.800	9.82	7.85	[0.8 - 2.5]
cashRatioTTM	0.153	1.500	-0.261	-0.391	[0.2 - 2]
debtRatioTTM	0.254	-1.500	5.76	-8.64	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	2.68	2.00	9.11	10.00	[0 - 30]
freeCashFlowPerShareTTM	1.939	2.00	9.03	10.00	[0 - 20]
debtEquityRatioTTM	0.542	-1.500	7.83	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.489	1.000	5.18	5.18	[0.2 - 0.8]
operatingProfitMarginTTM	0.215	1.000	7.69	7.69	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.510	1.000	8.28	8.28	[0.2 - 2]
assetTurnoverTTM	0.614	0.800	9.24	7.39	[0.5 - 2]
Total Score				9.93

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	28.49	1.000	7.22	0	[1 - 100]
returnOnEquityTTM	0.0866	2.50	-0.0956	-0.223	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.939	2.00	9.35	10.00	[0 - 30]
dividendYielPercentageTTM	2.80	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	2.68	2.00	9.11	10.00	[0 - 30]
payoutRatioTTM	0.721	1.500	2.79	-2.79	[0 - 1]
pegRatioTTM	-116.28	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.211	1.000	7.21	0	[0.1 - 0.5]
Total Score				3.84

Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.